Medical Properties Trust Inc
NYSE:MPW
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.07
6.37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Medical Properties Trust Inc
You don't have any saved screeners yet
Good day, and thank you for standing by. Welcome to the Q2 2021 Medical Properties Trust Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today, Mr. Charles Lambert. Please go ahead.
Thank you. Good morning. Welcome to the Medical Properties Trust conference call to discuss our Second Quarter 2021 Financial Results. With me today are Edward K. Aldag, Jr., Chairman, President and Chief Executive Officer of the company; and Steven Hamner, Executive Vice President and Chief Financial Officer. Our press release was distributed this morning and furnished on Form 8-K with the Securities and Exchange Commission. If you did not receive a copy, it is available on our website at www.medicalpropertiestrust.com in the Investor Relations section.
Additionally, we're hosting a live webcast of today's call, which you can access in that same section. During the course of this call, we will make projections and certain other statements that may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause our financial results and future events to differ materially from those expressed and/or underlying such forward-looking statements.
We refer you to the company's reports filed with the Securities and Exchange Commission for a discussion of the factors that could cause the company's actual results or future events to differ materially from those expressed in this call. The information being provided today is as of this date only, and except as required by the federal securities laws, the company does not undertake a duty to update any such information.
In addition, during the course of the conference call, we will describe certain non-GAAP financial measures, which should be considered in addition to and not in lieu of, comparable GAAP financial measures. Please note that in our press release, Medical Properties Trust has reconciled all non-GAAP financial measures to the most directly comparable GAAP measures in accordance with Reg G requirements. You can also refer to our website at www.medicalpropertiestrust.com for the most directly comparable financial measures and related reconciliations. I'll now turn the call over to our Chief Executive Officer, Ed Aldag.
Thank you, Charles and thank all of you for listening in today. By now most if not all of you have seen the reports from the likes of HCA, and Tenet and Universal. Their positive reports may have surprised some of the street but they certainly didn't surprise us. Our tenants are continuing the positive trends with very favorable operating results. But first let me discuss the growth of MPT. We're very excited to discuss another major push forward in our accreted growth strategy, investing more than $3.6 billion year-to-date, and more than $7 billion at the beginning of 2020 and yet growth for the sake of growth is not consistent with the way we've built MPT.
Our ideals have always been immediately accretive. Not only did MPT generate growth in FFO per share in excess of 20% last year, but we have grown both NFFO and AFFO per share well in excess of 10% year-over-year in the first half of 2021. This is the strategy we put in place more than 18 years ago, and we have not deviated from it. In the 10-year period ending the first quarter of this year, our normalized FFO per share grew at an annualized rate approaching 9%. Over the same time span, our AFFO per share grew at 6% annually. Now let me turn our attention to the operating results of our tenants.
EBITDARM coverage for our same-store acute care hospitals, which make up 72% of our portfolio increased 31% year-over-year on a trailing 12 month basis. These numbers include all of the grants received by our tenants. It does not include any Medicare advances. These grants, as you will recall have essentially reimbursed hospitals for the time period last year that they were shut down at the request of governments around the world. The first quarter 2021 lease coverage was 3.31 times for our acute care sector.
This includes the grants that were recognized by the tenants and expensing the extraordinary COVID expenses. The EBITDARM coverage for the acute care sector increased almost 22% quarter-over-quarter, demonstrating the same type of trajectory that we have seen from previously reported public company filings for hospital operators, acute care operators EBITDARM for same-store increased by more than $400 million year-over-year.
Our LTACH portion of our portfolio, which only represents 1.5% of the total portfolio, as a group continue to perform at the top of their historical coverages. The same-store EBITDARM increased by more than $25 million year-over-year and generated a trailing 12 month coverage of almost three times and an increase of almost 40 basis points quarter-over-quarter. The earth [ph] sector also continues to show strong performance. The EBITDARM for the trailing 12 months ending the first quarter of 2021 showed a slight improvement over 2020. The coverage continued to be strong at more than two times, which was a slight increase over the fourth quarter of 2020.
We certainly want to continue the policy of not divulging proprietary and nonpublic information on any of our tenants. But I do want to give you some more information on our largest tenants. So in alphabetical order, Circle continues to outperform our expectations on their integration of the BMI portfolio we acquired in January of 2020. Their total portfolio coverage is strongly above two times, their cash balances are higher today than they were at 12/31/20. You may have also seen that the American based healthcare company Centene has acquired 100% of the remaining shares of Circle that they did not already own.
Ernest continues to generate some of the strongest EBITDARM coverages in its history. The coverages are approaching three times and increased quarter-over-quarter by more than 30 basis points. Their liquidity also remains very strong. Healthscope continues its upward trajectory in lease coverage with numbers in line with pre-COVID coverages. LifePoint continues its strong operational position with coverages well in excess of pre-COVID numbers. EBITDARM coverages increased quarter-over-quarter by 40 basis points. Their liquidity position is one of the strongest in the MPT portfolio. MEDIAN, one of our strongest performers throughout 2020 continues its steady and strong performance with coverages very near their historical highs.
Prime's current EBITDARM coverages are well above their historical highs, their quarter-over-quarter coverage increased by more than 50 basis points, and the overall coverage is well in excess of our average acute care sector. Prospect has a very strong liquidity position and is generating coverages about 15 basis points above last quarter, their overall coverage is well above historical highs with MPT.
Steward performance tracks right in line with what we're seeing from our other operators. Their quarter-over-quarter coverage showed a more than 16 basis points increase. Their total coverage is also at an all-time high with MPT. [Indiscernible] performance has continued its historical levels with overall coverage well in excess of the average of our other post-acute operators.
With the recent announcement of pending acquisitions in the U.S., our U.S. portion of our total portfolio is expected to be approximately 61%. The acute care sector is projected to be 72% and our behavioral health 11% once we close on the Miami acute care hospitals and the Springstone transaction, we continue to be very bullish on our tenants and their performance, our balance sheet and liquidity management and our very calculated accretive growth strategy. I'll now turn it over to Steve, he will walk you through the details of our financial results. Steve?
Thank you, Ed. This morning we reported normalized FFO of $0.43 per diluted share for the second quarter of 2021, a 13.2% increase versus last year's second quarter result, which itself was a 23% increase over the comparable 2019 period.
Importantly, our AFFO per share increased by a similar 13.3% versus the second quarter of 2020, which along with our already attractive dividend payout ratio of only 82% continues to create capacity for sustained dividend growth. Adjusted for all mid quarter transactions, including in particular the closing of the Priory sale leaseback as if they all occurred on April 1, normalized FFO for the second quarter would have been $0.44 or an annualized $1.76 per share. The high end of our estimated normalized FFO annualized run rate.
As a reminder, our run rate guidance of $1.72 to $1.76 per share is an estimate of the expected annual FFO for our in place assets, plus other assets that are either under development or subject to binding acquisition agreements. Neither of which of course are included in our pro forma second quarter $0.44 per share.
We do plan to update our run rate guidance for the effects of our recently announced Springstone, Steward Southeast Florida and other transactions. Once we have more clarity about the amount, terms, and timing of certain expected capital recycling activities. We remain hopeful that will be before year-end. But under any reasonable set of assumptions about capital sourcing, we expect these transactions to be solidly accretive to per share earnings and FFO, consistent with how we have managed this business for every single acquisition we have made since forming Medical Properties Trust.
Before going into more detail about access to capital, I'll just mention a few other items related to the results for the second quarter. First, we recorded a $43 million adjustment to our estimate of net deferred tax liabilities related almost exclusively to the United Kingdom's increase in its corporate income tax rate from 19% to 25%. We do not expect discharge to have any material impact on our foreseeable cash results.
Second, as we do each quarter, we recognize the change in the market value of our investment in the securities of Aevis the parent of our tenant Swiss Medical Network. This quarter being a $2.1 million decline from the end of the first quarter.
Finally, I'll point out that included in the $18.7 million in property related expenses for the quarter is approximately $16 million for annual property insurance premiums, property taxes, ground lease payments, and other impositions, which are built back to tenants and included as revenue in real estate interest and other income a $1 for $1 offset.
Since our last earnings update, we have announced more than $2 billion in new investments. Virtually all in the U.S. at a weighted average GAAP yield approximating 8.7% and first year cash yield of about 7%. Activity began with the announcement of a $950 million investment in 18 inpatient behavioral hospitals, and an equity interest in the operator as Springstone.
In addition to the very attractive terms from the initial 18 hospital portfolio, MPT immediately gains the scale necessary to rapidly grow in new markets in the inpatient behavioral health business, as the U.S. seeks to address unmet and growing demand for acute behavioral care. Following this announcement, we announced plans to acquire five general acute care hospitals to be operated by Steward in the Miami and Fort Lauderdale area for approximately $900 million. These are truly critical community assets that are essential to the dense, growing and ageing populations of the region. And through the existing master lease we'll further diversify and strengthen our credit profile with Steward.
This morning, we also announced a couple of smaller acquisitions, both of which have closed already. First, we acquired for $215 million a network of four hospitals and two medical office buildings in densely populated areas of Los Angeles from Pipeline Health. Pipeline has carefully structured its operations to successfully accommodate an otherwise underserved population that has few attractive alternatives for hospital care.
In addition, we added one hospital in Scotland to our Circle Health relationship for £15.6 million. As we have been predicting, almost all of our recent acquisitions have been in the U.S. that's an important point, because among other considerations when we invest away from the U.S. as has been the case in the last couple of years, we purposely over lever with very low rated debt in local currency, which provides a natural currency hedge.
In anticipation of over equitizing U.S. acquisitions, where lease yields are higher and can more profitably absorb the higher cost, but necessary equity funding. We have been doing this successfully since our first non-U.S. acquisition in 2013. So, during the last couple of years when our acquisitions have coincidentally been relatively weighted away from the U.S., and our leverage measures have therefore predictably unexpectedly increased. We have at the same time been preparing for the over equitization that is part of our U.S. activities.
And today, we have a very attractive position in so far as liquidity and other non-debt sources of permanent funding including. As of June 30, we have $720 million in unencumbered cash on the balance sheet. And this does not include about $350 million in repayment proceeds from Priory that are due by the year-end or a $135 million in proceeds from the sale of our Olympia Hospital in Washington state to the largest operator in that state. This is under binding contract subject only to regulatory approval and will reflect the gain on sale of approximately $30 million. Nor does it include another $30 million in proceeds from the sale of a smaller hospital that we expect will close imminently.
So between cash on hand and pending contractual proceeds in the near-term, we have total cash of about $1.1 billion available for our pending acquisitions. In addition, we are able to issue shares under our ATM program at very low cost relative to an underwritten offering. And finally, but critically, I mentioned a few minutes ago that we remain expectant of completing certain capital, recycling transactions during the remainder of this year. We expect to generate $1 billion or more in equity like capital from joint venture like arrangements.
While we are not prepared today to disclose any details about possible joint ventures, there are independent indications that the market for hospital assets is robust. These indications include Ramsey's bids to acquire Spire in the U.K. Apollo invest a LifePoint acquisition of Kindred Healthcare and an actual bidding war going on in Australia for Australian Unity's Healthcare Property Trust. The same conditions that have driven our own unmatched growth and hospital assets are also rapidly attracting sovereign, institutional and other large sophisticated investors toward hospital assets.
We hope to be in a position soon to quantify how this rapidly expanding market will provide equity funding for our acquisitions at a cost considerably below that of conventional underwritten common equity offerings. So depending on whether these transactions actually close consistent with our current estimates, and there is no assurance that they will and the timing of any such closings. Our expectation is that we will have sufficient capital to complete all of our pending acquisitions, lower our leverage to six times or better, and provide substantial liquidity for future acquisitions all without unwarranted dilution of our current shareholders.
But because we do not control timing of regulatory approvals or other conditions to completion of our pending acquisitions, or the progress of potential joint venture counterparties, or other unforeseen events. We have also prudently provided liquidity backstops in the form of $2.3 billion in interim and revolver facilities that would temporarily fund these transactions. If the sequence of events so requires.
We strongly favor the cost of equity capital available to us in the private real estate market, such as joint ventures over the public market at current pricing. And we have carefully and thoughtfully preplanned our capital strategies to avoid the need to issue common shares in an unattractive market. It's a very good place to be in.
I'll now turn the call back to the operator for questions.
[Operator Instructions]. Your first question comes from the line of Jordan Sadler with KeyBanc Capital Markets.
Thank you and good morning, everyone.
Good morning, Jordan.
Good morning. Can you provide a little bit more insights surrounding the financing strategies, Steve? I heard your commentary, it sounds like you've got a lot going on. But the piece I'm struggling with a little bit is the relative attractiveness of the cost of equity. And I know that the company issued equity below these levels, maybe $1 below, $0.75 below current levels earlier in the year for the Priory transaction and some other stuff that was going on. So the stock is up. And I'm kind of curious why you would not have taken the opportunity to avail yourself of the ATM proceeds kind of we discussed on the last call, given all of the investment activity that appears to be already identified, not even speaking to the stuff that may be in the pipeline. Thanks.
So I think, Jordan, if you allow me, I'll rephrase the question is, why would we wait and let the joint venture and perhaps some other strategies play out over a period of time versus immediately tap the underwritten equity markets at today's pricing? And the answer is, we have both available. The difference in cost, overall long-term cost of equity of the so called private option, the JV option, versus selling it today's price, which is not today's price, as you know, there would be a significant discount, there's a significant cost.
Our view is we can come back to that if necessary. We're hopeful and don't think it will be necessary in any significant way. So why not accomplish a number of things with the joint venture strategy. The first of those, the only one we talked about so far today is the cost advantage, it is a significant cost advantage.
Secondly, it allows us to manage to a certain meaningful extent, the concentration questions that some have about the portfolio. And then thirdly based on again, the pricing that we expect to achieve, it validates very significantly, the underlying inherent value that we've created since initially acquiring certain assets, very similar to what we did three years ago, with the very similar Primonial transaction, where at that time, we were earning eight plus percent on our investment. And because of management of the portfolio seasoning of the operator, further strategic steps that we have taken, that cap rate had come in by 25%.
So we were able to sell the MEDIAN exposure for 6%. The numbers are not exactly lined up, equivalent to 8% versus 6%, but they're very similar for the transactions we're expecting in the joint ventures.
Well, Jordan let me say just slightly differently. It's the same thing. We certainly aren't the first management to think their stock is undervalued. We certainly do, as a lot of you on this call have written about, when we announced the acquisitions, many people were waiting for us to do an equity offering, we believe that the stock has been artificially pressured in that regard. We have access as to other capital we had planned on this, it's much cheaper than raising capital through what we believe is current underpriced stock. So we'll take advantage of that. And as we have already planned, and we'll not have to do an equity offering in the near future.
Hey guys, thanks for that. This is our third here 24.32 with Jordan. Just one more question. As 2Q looks like sort of represented around 27% to 28% of total revenue. Do we maybe expect to see Steward exposure decline after some of the announced acquisitions close in the second half, and maybe some other activity that you're expecting?
So all else equal and in a vacuum, yes if we add $900 million in Miami investments to our existing Steward exposures, then that's going to increase, obviously that arithmetical percentage, we do have strategies, none are binding and we're not making any predictions this morning. But we do expect to see over coming quarters the Steward exposure continued to decline, as it has over the last couple of years. Perhaps not quite as dramatically as it has, but again, over the next two to three quarters, plus or minus we expect Steward exposure to decline.
Great, thanks.
Your next question comes from the line of Joshua Dennerlein with Bank of America.
Yes, good morning, guys. Hope everyone's doing well. Maybe just kind of follow-up on the funding question there, curious do you guys have ever thought about using like forwards whether it's ATM or overnight to kind of mocking, mocking funding?
Yes, we do. But again the first question to ask if you're talking about forwards to do forward, obviously, I know everybody knows you do an offering. And just based on what we've said, this morning already, we don't think we're in a position, we're doing a significantly sized underwritten overnight or otherwise offering is the best thing for our shareholders. But every time in the recent past, going back a couple of years that we have done an underwritten offering, we absolutely do consider the advantages of having some type of forward component to it. And it hasn't been, the benefits have not been helpful to us, primarily because we had an immediate use of proceeds for 100% for the offered amount.
Okay, thanks. And for the acquisition market, I guess what are you guys seeing out there for the second half this year, I'm curious what your pipeline looks like?
Yes, Josh, it still is active. It's still thrown. We obviously didn't make any additional announcements about that today. We've got a lot on our plate right now. And we'll finish this up. But it is still a very, very strong market.
Okay. And have cap rates changed at all? It sounded like last time we kind of spoke there was just like more interest in the U.S. market. So curious if those are coming down at all?
Yes, they really haven't changed, Josh. It's not that we have more interest in the U.S. as we have said over the years, these things generally seem to take a long time to put together, we obviously can see further in the future than everybody else in this regard. And so we knew that these U.S. acquisitions were coming along wasn't that we were just specifically looking for a U.S., we just knew from a timing and placement standpoint that the U.S. acquisitions were falling in place right now.
Got it, thanks Ed, thanks Steve. Appreciate it.
Your next question comes from the line of Connor Siversky with Berenberg.
Good morning, everybody. Thank you for having me on the call.
Good morning.
Just starting in a high level, I know in the recent investment presentation, it was stated that Steward was seeing virtually a full recovery of patient traffic. And now that we have the Delta Variant spreading, you're seeing the curve go parabolic. There's some, there's a narrative out there now that some of the hospitals down in Louisiana and Florida are cutting back on electives. I'm just wondering if this is permeating through the operating base, what is the strategy to handle a sustained spike in infections? And if you could extrapolate that out into what it could possibly look in rank coverage, that would be very helpful.
Yes, sure. Absolutely, Connor. So if you look at our entire portfolio all across the world, not just in the U.S., but we're not having any issues in any of our facilities, with the Delta variant in any gross exaggeration of additional patients in the hospital. I actually had conversations with every one of our major operators within the last couple of weeks. And that just isn't the case.
Obviously, some of you may have seen Scott Godlip's interview yesterday in which he talked a lot about the Delta Variant and while it is an increased infection primarily among the unvaccinated, it's not in, it currently is not any more dangerous than the original COVID was, we've come a long way since this time last year and learning how to treat patients and so it is not an issue from an operating standpoint, in any of our hospitals anywhere around the world.
Okay, that's helpful. And then moving on to behavioral health, you had mentioned in the prepared remarks that there's this growing need within the United States in particular, and I'm wondering what the competition base looks like right now, if you're starting to see more eyes turn to those assets. And whether or not those we could expect those 9% yields or so to come down in the years ahead?
Well, Connor particularly here in the U.S., there's not much supply out there. We wanted to be this big involved in behavioral health for a long time, particularly since the ACA was passed. But it just hasn't been available to us, there have been one-offs, but just not worth the time. So on this particular very strong portfolio, there was a lot of competition for this particular portfolio, we expect that there will continue to be, there just aren't this sized portfolios out there. So we're very delighted to have been able to won this particular process.
Okay, and last one for me, just on the sale of Capella Medical Center, apologies if I missed this, any sense of what the pricing was on that deal or what it could look like?
We're selling the real estate, the fee interest in the real estate, and we did disclose its $135 million sale price cash proceeds. It's conditioned only on obtaining and approval in Washington, which we're all hopeful to have good reason to be hopeful is almost a pro forma approval because it is only real estate. The same buyer bought the operations earlier in the year.
Okay, okay. That clarifies, thank you.
Your next question comes from the line of Mike Mueller with JPMorgan.
Yes, hi. I'm just curious how deep is the pool of investors that you're talking to for the various JVs on safely to Steward assets?
It is - it's very big, frankly. And not only for the equity piece very deep including mostly in fact, global institutions, whether they be infrastructure funds, sovereign wealth funds, large public and private advised pension funds from truly across the globe. We see the same level of interest. And this is really interesting, helpful. From our perspective, we see the same level of interest from traditional lenders, who I say traditional with respect to the typical for big food groups or real estate investing that in the past have not been participating in hospital real estate. And so we have literally dozens of interested potential lenders for secured financing on this real estate.
Got it. Okay, that was it. I appreciate it.
Your next question comes from the line of Michael Carroll with RBC Capital Markets.
Yes, thanks. Just after Mike's question, I want to talk a little bit about the JVs. I know MPW has been working on this for the past year, year plus or so. I mean, is this taking longer than you expected? I mean, are these deals more complex than for these making - taking time for these parties to work through or is this by design is as MPW just wanting to get these deals done by the end of the year. So I mean, this is kind of what you always thought in the first place.
So Mike, it really hasn't. Remember we went through the pandemic last year, and everybody put the entire world on hold. So if you actually look at the time period that the world open back up and our direction on this, it has been much quicker than the promoting all of our transaction.
Okay. And then going back to, I guess some of the recent deals. Can you talk a little bit about the DLA on type transactions which you completed, I think Steve or Ed, I think you mentioned that that these were hospitals really for to serve the population that doesn't get a lot of access to healthcare? Can you kind of explain that and how these buildings are different from some other general acute care hospitals?
Absolutely, and you stated it correctly. These are hospitals and not to be pejorative, but Inner City LA basically that without these particular facilities, very many hundreds of 1000s of population around these facilities would have very limited alternatives. But the alternatives would be to try to access the competing hospitals, particularly the teaching, the USC and UCLA hospitals and others in the area, which are already running at very, very high capacity. So we look at this real estate, when you consider a good real estate investment as the absolute highest and best long-term use for this real estate is operating as hospitals.
And similar to what we described with Prospect a couple of years ago, and why we would, why we would invest with an operator that has a relatively higher level of exposure, for example to Medicaid. Pipeline Health has developed a strategy and operational abilities over the last several years that can operate and have operated these hospitals very, very profitably.
So we think the downside to these types of investments is very, very limited, because there are operators, including pipeline and others who can and have operated very profitably, very high margins and coverages for us and the community truly cannot do without these hospitals.
Mike, we spend a lot of time on these particular facilities they have, they came to us before COVID obviously with COVID everybody stopped but we spend a lot of time underwriting these facilities. They're obviously not the big beautiful shiny neighborhoods, but they are very nice neighborhoods while they are lower income neighborhoods, the people take great care in them, the neighborhoods are clean, the people that live in the neighborhood, their houses are very well kept and they're very, very proud of these hospitals and the healthcare that they're able to get, they're very important to this community.
Okay, and then I guess taking a - I guess taking that board I mean, is there other types of deals like this out there that you're looking at? I mean is this a segment that you can grow with this specific operator and I know that they have some assets outside of LA in Illinois, is that something that you're interested in, too?
So that's a very good question, Mike. And while they certainly do have other assets, they haven't been made available to us, we haven't spent any time underwriting those particular ones. But we do like our relationship with them and believe that is one that we can grow.
Okay, great. Thank you.
Your next question comes from the line of Lukas Hartwich with Green Street.
Thanks, good morning.
Good morning, Lukas.
Good morning. In terms of continued financial support from the government for the healthcare industry, how important is that for MPW today?
Yes, it's not at all. Lukas, it is I know you're new to the story. So you may not have listened to some of the previous earnings calls that we've had about this particular issue. But our hospitals are performing exceptionally well. We have a number of operators that actually gave back not only the advances, but some of the grants that they received, our hospitals are in great financial situation. As we said, back in April and May of last year, we knew that the patients would all come back as soon as the government's reopened of hospitals, while the world called them elective surgery, that only meant that if you didn't have them done, you wouldn't die the next day.
But these were all medically necessary procedures. And so we're back at volumes of pre-COVID levels, their lines out the door. And so we feel very good about where all the operators are.
That's really helpful. And then my second question is just in terms of MPW's tenant base such as heavily concentrated and for-profit providers, I was just hoping you could talk about the opportunity set on the nonprofit side of things?
Yes, if you look back to the history of founding this company, probably one of the biggest surprises to me personally has been that we haven't had as big an impact with the not-for-profits. Now that has changed in recent years. And we've got a fairly decent sized number of not-for-profit operators now. And they recognize that it's like some not-for-profit operators recognize that it's a great piece of their overall capital stack. We hope that we can continue to increase that certainly, because of the portfolio that we have now.
It gives us a better entree into some of the other not-for-profits. But they do move at a different pace than the for-profits do. They're generally much slower in the entire process. They generally have larger boards and getting all of them on board. So it is something that that we think is an avenue for us. But it won't grow as fast as we've grown elsewhere.
Thanks and do you have a rough split between profit versus nonprofit for the MPW portfolio?
Yes, it's a very small percentage in not-for-profit, I think I'll total we've got about seven not-for-profit operators.
Great, thank you so much.
Your next question comes from the line of Michael Lewis with Truist Securities.
Great, thank you. I wanted to follow-up on something you just kind of talked about, about given the grants back, I noticed in your supplemental, your EBITDARM coverage went up sequentially to three times from two and a half, that 4Q 22.5 coverage last quarter in the supplemental that showed us 3.1 times. I'm guessing I guess that's the difference there is that maybe some grants were returned, and you went back and adjusted that number, is that what happened or is there something else going on there?
Yes, so it's a little bit of all of the above. It's recognizing some of the COVID expenses, the extraordinary COVID expenses, and they're giving back, some of our operators giving back some of the grants.
Okay, that makes sense. I wanted to ask to, I don't know if you touched on this about the tax rate change charge during the quarter. It was backed out in the normalized FFO. But I was just wondering about that. Was there any portion of that that was a tax charge this quarter or is it adjusting for how you maybe booked expenses in the past and I'm just wondering if this is kind of a one-time thing or if you have any additional tax risk or any kind of risk in that line item?
No, this is the U.K. attempting to find every dollar it can to pay for COVID, which they have spent upwards of $100 billion on. So they increased their corporate tax rate from actually a couple of quarters ago, the 17% they bumped it up to 19% and then during this last quarter, they bumped it all the way up to 25%, the $43 million increase the charge that we took reflects all else equal, what we would pay, if we tomorrow for example sold all of our assets at the asset level in the U.K. for basically for what we paid for them.
So what that says is there's built in gains to what we paid. And so the $43 million represents that tax differential, on such presumed capital gain. So because A, we don't expect to sell the properties at all and B, if we did, we would structure the sales in a much more tax advantaged method, which would include selling the equity of the owner, not the assets themselves and continue to defer that tax. That's why I said earlier, we don't see any foreseeable in whatever term, near-term, long-term whatever, we don't see any impact, any cash impact from the tax rate change.
Okay, got it. That's clear. All my other questions have been answered. Thank you very much.
Thanks, Mike.
There are no additional questions on the phone line. I would now like to turn the call back over to Mr. Ed Aldag for closing remarks.
Thank you, Susanne and again thank all of you for listening in today, thank you for your questions, if anything comes up post the call, please don't hesitate to reach out to us. Thank you very much.
Ladies and gentlemen, this does conclude today's conference call. You may now disconnect.